Email - Biogen submits aducanumab data for FDA review

Donate

Enews from the Alzheimer's Association

Having trouble viewing this message? You may view it as a web page. You may also view e-news archives.
To prevent mailbox filters from deleting your Alzheimer's Association email communications, please add alzheimers_enews@alz.org to your address book.

24/7 Helpline: 800.272.3900

Biogen submits aducanumab data for FDA review

Biogen announced the completion of its regulatory filing to the U.S. Food and Drug Administration (FDA) on aducanumab for the treatment of dementia and mild cognitive impairment due to Alzheimer's. If approved, aducanumab would become the first therapy to reduce the cognitive and functional decline of people living with the disease.

Mental and physical exercise may help slow cognitive decline

Experts say that you may be able to slow or stall age-related loss of cognitive function with mental and physical exercise, diet and other activities. The Alzheimer's Association U.S. POINTER study seeks to evaluate whether lifestyle interventions that simultaneously target many risk factors protect cognitive function in older adults at increased risk for cognitive decline.

Help fight Alzheimer's

Give Now

Get Involved

Your Local Community

Find a chapter here

Shop AmazonSmile and help fight Alzheimer's

When you shop on AmazonSmile, the AmazonSmile Foundation will donate 0.5% of the purchase price of eligible products to the charitable organization of your choice, including the Alzheimer's Association. In order to access this feature on your Amazon app for iOS and Android, select the charity on your desktop version of AmazonSmile.

More Resources:

Stages of Alzheimer's

Behaviors

Coping Strategies

Care Training


My Preferences:
Unsubscribe To stop receiving our weekly e-newsletter, simply unsubscribe.		Subscribe Was this e-newsletter forwarded to you? Subscribe to get it weekly.